Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (77)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Morse, M. A.
Right arrow Articles by Chung, F.-L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Morse, M. A.
Right arrow Articles by Chung, F.-L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1990 Oxford University Press

other

Characterization of a glucuronide metabolite of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and its dose-dependent excretion in the urine of mice and rats

Mark A. Morse, Karin I. Eklind, Mary Toussaint, Shantu G. Amin and Fung-Lung Chung 1

Division of Chemical Carcinogenesis, Naylor Dana Institute for Disease Prevention, American Health Foundation Valhalla, NY 10595, USA

1To whom all correspondence should be addressed

Following analysis by reversed-phase HPLC, a previously uncharacterized metabolite of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) was found in the urine of A/J mice treated with NNK. Treatment with ß-glucuronidase converted the metabolite to a peak that co-eluted with 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL). Treatment with sulfatase or ß-glucuronidase plus saccharic acid 1,4-lactone did not change the retention time of the metabolite. These data suggested that the unknown metabolite was a glucuronic acid conjugate of NNAL. Upon isolation and purification of larger quantities of the metabolite from the urine of A/J mice, CD-1 mice and F344 rats, 1H and 13C NMR and MS confirmed that the unknown metabolite was 4-(methylnitrosamino)-1-(3-pyridyl)-1-butyl ß-D-glucopyranosiduronic acid (NNAL Glu). To determine the quantitative relationship between NNK dose and NNAL Glu production and to compare the importance of glucuronidation relative to other metabolic pathways, [5-3H]NNK was administered to F344 rats and A/J mice at doses of 500–0.005 µmol/kg. At 500 µNNAL Glu accounted for 22% of the total urinary excretion of NNK in A/J mice, and for 8% in F344 rats 48 h after dosing. The proportions of excreted glucuronide and NNAL decreased with diminishing doses of NMK, yielding undetectable levels of each metabolite in both mice and rats at a dose of 0.005 µmol/kg NNK. Since substantial amounts of metabolites formed via {alpha}-hydroxylatlon and N-oxidation pathways were observed at the lower doses of NNK, these data demonstrate that NNAL glucuronidation is a quantitatively unimportant metabolic pathway at low doses of NNK.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
I. Stepanov, P. Upadhyaya, S. G. Carmella, R. Feuer, J. Jensen, D. K. Hatsukami, and S. S. Hecht
Extensive Metabolic Activation of the Tobacco-Specific Carcinogen 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanone in Smokers
Cancer Epidemiol. Biomarkers Prev., July 1, 2008; 17(7): 1764 - 1773.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
S. S. Hecht, S. G. Carmella, I. Stepanov, J. Jensen, A. Anderson, and D. K. Hatsukami
Metabolism of the Tobacco-Specific Carcinogen 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanone to Its Biomarker Total NNAL in Smokeless Tobacco Users
Cancer Epidemiol. Biomarkers Prev., March 1, 2008; 17(3): 732 - 735.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
E. M. Leslie, G. Ghibellini, K.-i. Nezasa, and K. L.R. Brouwer
Biotransformation and transport of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in bile duct-cannulated wild-type and Mrp2/Abcc2-deficient (TR ) Wistar rats
Carcinogenesis, December 1, 2007; 28(12): 2650 - 2656.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
C. J. Gallagher, J. E. Muscat, A. N. Hicks, Y. Zheng, A.-M. Dyer, G. A. Chase, J. Richie, and P. Lazarus
The UDP-Glucuronosyltransferase 2B17 Gene Deletion Polymorphism: Sex-Specific Association with Urinary 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanol Glucuronidation Phenotype and Risk for Lung Cancer
Cancer Epidemiol. Biomarkers Prev., April 1, 2007; 16(4): 823 - 828.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. Wiener, J.-L. Fang, N. Dossett, and P. Lazarus
Correlation between UDP-Glucuronosyltransferase Genotypes and 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanone Glucuronidation Phenotype in Human Liver Microsomes
Cancer Res., February 1, 2004; 64(3): 1190 - 1196.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
D. Wiener, D. R. Doerge, J.-L. Fang, P. Upadhyaya, and P. Lazarus
CHARACTERIZATION OF N-GLUCURONIDATION OF THE LUNG CARCINOGEN 4-(METHYLNITROSAMINO)-1-(3-PYRIDYL)-1-BUTANOL (NNAL) IN HUMAN LIVER: IMPORTANCE OF UDP-GLUCURONOSYLTRANSFERASE 1A4
Drug Metab. Dispos., January 1, 2004; 32(1): 72 - 79.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
Z. Wu, P. Upadhyaya, S. G. Carmella, S. S. Hecht, and C. L. Zimmerman
Disposition of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) in bile duct-cannulated rats: Stereoselective metabolism and tissue distribution
Carcinogenesis, January 1, 2002; 23(1): 171 - 179.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
Q. Ren, S. E. Murphy, Z. Zheng, and P. Lazarus
O-Glucuronidation of the Lung Carcinogen 4-(methylnitrosamino)-1- (3-Pyridyl)-1-Butanol (nnal) by Human Udp-Glucuronosyltransferases 2b7 and 1a9
Drug Metab. Dispos., November 1, 2000; 28(11): 1352 - 1360.
[Abstract] [Full Text]

Home page
 CarcinogenesisHome page
P. Upadhyaya, S. G. Carmella, F.P. Guengerich, and S. S. Hecht
Formation and metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol enantiomers in vitro in mouse, rat and human tissues
Carcinogenesis, June 1, 2000; 21(6): 1233 - 1238.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
E. Schrader, K. I. Hirsch-Ernst, E. Scholz, G. F. Kahl, and H. Foth
Metabolism of 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in Primary Cultures of Rat Alveolar Type II Cells
Drug Metab. Dispos., February 1, 2000; 28(2): 180 - 185.
[Abstract] [Full Text]

Home page
 Drug Metab. Dispos.Home page
Q. Ren, S. E. Murphy, A. J. Dannenberg, J. Y. Park, T. R. Tephly, and P. Lazarus
Glucuronidation of the Lung Carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) by Rat UDP-Glucuronosyltransferase 2B1
Drug Metab. Dispos., September 1, 1999; 27(9): 1010 - 1016.
[Abstract] [Full Text]

Home page
 CarcinogenesisHome page
P. Upadhyaya, P. M.J. Kenney, J. B. Hochalter, M. Wang, and S. S. Hecht
Tumorigenicity and metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol enantiomers and metabolites in the A/J mouse
Carcinogenesis, August 1, 1999; 20(8): 1577 - 1582.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
M. Meger, E. Richter, W. Zwickenpflug, C. Oehlmann, M. B. Hargaden, Y. I. A-Rahim, and E. S. Vesell
Metabolism and Disposition of 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanone (NNK) in Rhesus Monkeys
Drug Metab. Dispos., April 1, 1999; 27(4): 471 - 478.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
S. S. Hecht, S. G. Carmella, M. Chen, J. F. D. Koch, A. T. Miller, S. E. Murphy, J. A. Jensen, C. L. Zimmerman, and D. K. Hatsukami
Quantitation of Urinary Metabolites of a Tobacco-specific Lung Carcinogen after Smoking Cessation
Cancer Res., February 1, 1999; 59(3): 590 - 596.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
L. M. Winn, P. M. Kim, and P. G. Wells
Investigation of the Tobacco-Specific Carcinogen 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanone for In Vivo and In Vitro Murine Embryopathy and Embryonic ras Mutations
J. Pharmacol. Exp. Ther., December 1, 1998; 287(3): 1128 - 1135.
[Abstract] [Full Text]

Home page
 Hum Exp ToxicolHome page
S. Atawodi and E. Richter
Bacterial reduction of N-oxides of tobacco- specific nitrosamines (TSNA)
Human and Experimental Toxicology, April 1, 1996; 15(4): 329 - 334.
[Abstract] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.